ArticlePloS one2018
Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Autoantibodies in cancer: a systematic review of their clinical role in the most prevalent cancers.Frontiers in immunology · 2024Pooled it
- EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2022Pooled it
- Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.The European respiratory journal · 2021Trial
- Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma.British journal of cancer · 2026Article
- Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil.PloS one · 2025Article
- Biomarkers in lung cancer diagnosis and bronchoscopy: Current landscape and future directions.Cancer biomarkers : section A of Disease markers · 2025Review
- Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules.Journal of thoracic disease · 2023Article
- Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges?Cancers · 2023Review
- The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.Biomedicines · 2022Review
- Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.American journal of respiratory and critical care medicine · 2021Article
- Modeling the Impact of Delaying the Diagnosis of Non-Small Cell Lung Cancer During COVID-19.The Annals of thoracic surgery · 2021Article
- Liquid biopsies to distinguish malignant from benign pulmonary nodules.Thoracic cancer · 2021Review
- Review
- Molecular biomarkers in early stage lung cancer.Translational lung cancer research · 2021Review
- The National Cancer Institute Early Detection Research Network: Two Decades of Progress.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Review
- Biomarkers for Lung Cancer Screening and Detection.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician's Point of View.Journal of clinical medicine · 2020Article
- Noninvasive biomarkers for lung cancer diagnosis, where do we stand?Journal of thoracic disease · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients who have incidentally detected pulmonary nodules and an estimated intermediate risk (5-60%) of lung cancer frequently are followed via computed tomography (CT) surveillance to detect nodule growth, despite guidelines for a more aggressive diagnostic strategy. We examined the cost-effectiveness of an autoantibody test (AABT)-Early Cancer Detection Test-Lung (EarlyCDT-LungTM)-as an aid to early diagnosis of lung cancer among such patients.
methodsWe developed a decision-analytic model to evaluate use of the AABT versus CT surveillance alone. In the model, patients with a positive AABT-because they are at substantially enhanced risk of lung cancer-are assumed to go directly to biopsy, resulting in diagnosis of lung cancer in earlier stages than under current guidelines (a beneficial stage shift). Patients with a negative AABT, and those scheduled for CT surveillance alone, are assumed to have periodic CT screenings to detect rapid growth and thus to have their lung cancers diagnosed-on average-at more advanced stages.
resultsAmong 1,000 patients who have incidentally detected nodules 8-30 mm, have an intermediate-risk of lung cancer, and are evaluated by CT surveillance alone, 95 (9.5%) are assumed to have lung cancer (local, 73.6%; regional, 22.0%; distant, 4.4%). With use of the AABT set at a sensitivity/specificity of 41%/93% (stage shift = 10.8%), although expected costs would be higher by $949,442 ($949 per person), life years would be higher by 53 (0.05 per person), resulting in a cost per life-year gained of $18,029 and a cost per quality-adjusted life year (QALY) gained of $24,330. With use of the AABT set at a sensitivity/specificity of 28%/98% (stage shift = 7.4%), corresponding cost-effectiveness ratios would be $18,454 and $24,833.
conclusionsUnder our base-case assumptions, and reasonable variations thereof, using AABT as an aid in the early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules who are estimated to be at intermediate risk of lung cancer and are scheduled for CT surveillance alone is likely to be a cost-effective use of healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.